Medscape Conference Coverage, based on selected sessions at:

CROI 2009: 16th Conference on Retroviruses and Opportunistic Infections

February 08 - 11, 2009; Montreal, Canada

This activity is not sanctioned by, nor a part of, the 16th Conference on Retroviruses and Opportunistic Infections. Conference news does not receive grant support and is produced independently.

Conference News

  • Maternal HAART Reduces Mother-to-Child HIV Transmission

    In a separate study, investigators attempted to determine the optimal antiretroviral therapy regimen for women who had received a single dose of intrapartum NVP.
    Medscape Medical News, February 24, 2009
  • Early Virologic Response Predicts Sustained Response

    Early virologic response to treatment for hepatitis C virus (HCV) infection is equally predictive of sustained virologic response in patients coinfected with HIV as it is in patients with HCV monoinfection.
    Medscape Medical News, February 24, 2009
  • Debate Over Risk for CVD With Abacavir Continues

    Analyses from 4 studies and others were presented; the studies showing a signal of cardiovascular disease risk were generally prospective and more robust in size.
    Medscape Medical News, February 19, 2009
  • Treating Primary HIV Changes Disease Course

    Initiation of highly active antiretroviral therapy during primary HIV infection, and then stopping it, appears to alter the natural history of disease progression in a beneficial way.
    Medscape Medical News, February 19, 2009
  • Theoretical Limit of HAART Has Been Reached

    Researchers should move on to finding and eliminating the stable reservoirs of HIV, Robert Siliciano, MD, said during the opening lecture at the 16th Conference on Retroviruses and Opportunistic Infections.
    Medscape Medical News, February 18, 2009
  • Early Initiation of Anti-HIV Therapy Improves Survival

    HIV-infected patients with a CD4 cell count higher than 500 who defer starting highly active antiretroviral therapy have a 36% higher risk of death than those who start therapy sooner.
    Medscape Medical News, February 12, 2009
  • Potential Replacements for Ritonavir Advance

    Early clinical trials for metabolic inhibitors that might replace ritonavir in "boosting" other HIV drugs are generating an unusual level of interest within the treatment community.
    Medscape Medical News, February 12, 2009
  • No Clinical Benefit of CD4 Cells Generated by IL-2

    First results of the ESPRIT and SILCAAT studies confirm no clinical benefit from additional CD4+ cells generated using interleukin-2 in conjunction with HAART.
    Medscape Medical News, February 11, 2009
  • High Semen HIV RNA When Plasma is Undetectable

    The belief that undetectable plasma HIV RNA means a lower risk of viral transmission through seminal fluid may hold true on a population level, but not when applied at the individual level.
    Medscape Medical News, February 10, 2009
  • Microbicide May Be First to Protect Against HIV Infection

    A post-hoc per-protocol analysis of PRO 2000 found a significant 36% reduction in HIV infection, but a more conservative intention-to-treat analysis showed results that only approached significance.
    Medscape Medical News, February 9, 2009

The materials presented here do not reflect the views of Medscape, LLC, or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape, LLC, and do not represent a publication of the 16th Conference on Retroviruses and Opportunistic Infections. These materials and the related activity are not sanctioned by the 16th Conference on Retroviruses and Opportunistic Infections or any commercial supporters of the conference and do not constitute an official part of that conference.